News from soligenix, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Aug 31, 2015, 07:00 ET

Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Aug 27, 2015, 07:15 ET

Soligenix Receives Additional NIAID Funding to Advance Development of OrbeShield™ in GI ARS

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Aug 19, 2015, 07:00 ET

Soligenix Receives Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Aug 12, 2015, 07:00 ET

Soligenix Announces Recent Highlights and Second Quarter 2015 Financial Results

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Aug 04, 2015, 07:30 ET

Soligenix Receives Orphan Drug Designation from the European Commission for SGX301 as a Treatment for Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Aug 03, 2015, 07:30 ET

Soligenix Enters into a $10 Million Equity Purchase Agreement

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Jun 23, 2015, 07:15 ET

Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Jun 02, 2015, 07:00 ET

Soligenix Announces Publication of Successful Application of its Heat Stabilization Technology to a Human Papillomavirus Vaccine

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

May 28, 2015, 07:00 ET

Soligenix Announces Collaboration with the University of Hawai'i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

May 14, 2015, 07:00 ET

Soligenix Announces First Quarter 2015 Highlights and Financial Results

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

May 13, 2015, 07:00 ET

Soligenix Announces Development Agreement with Emergent BioSolutions

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

May 04, 2015, 07:00 ET

Soligenix Announces Presentation and Poster at the 2015 Chemical and Biological Defense Science and Technology Conference in St. Louis, MO

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Apr 14, 2015, 07:00 ET

Soligenix Announces FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX203 in Pediatric Crohn's Disease

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Mar 24, 2015, 07:00 ET

Soligenix Announces Recent Accomplishments and Year-End 2014 Financial Results

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Mar 11, 2015, 07:00 ET

Soligenix Announces Publication of Successful Preclinical Efficacy and Immunogenicity Results for Ricin Toxin Vaccine

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Mar 05, 2015, 07:00 ET

Soligenix to Present at the 27th Annual ROTH Conference

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address...

Mar 03, 2015, 07:00 ET

Soligenix Announces Positive Recommendation by Data Review Committee on its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet...

Feb 13, 2015, 07:00 ET

Ricin Toxin Vaccine Poster Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Feb 11, 2015, 07:00 ET

Preclinical Melioidosis Results Presented at the 2015 ASM Biodefense and Emerging Diseases Research Meeting in Washington, DC

Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical...

Feb 05, 2015, 07:00 ET

Soligenix to Present at the 17th Annual BIO CEO & Investor Conference in New York City

 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late stage biopharmaceutical company committed to developing products that address...